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Abstract
Background: Polycystic ovary syndrome (PCOS) is associated with insulin resistance
and elevated risk of cardiovascular disease and diabetes. Chronic inflammation has
been observed in PCOS in several studies but there is also opposing evidence and a
dearth of research in Indians.
Objective: To estimate chronic inflammation in PCOS and find its relationship with
appropriate anthropometric and biochemical parameters.
Materials and Methods: Chronic inflammation was assessed in 30 women with
PCOS (Group A) and 30 healthy controls (Group B) with highly sensitive C-reactive
protein (hsCRP), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFα), and platelet
microparticles (PMP). In group A, the relationship of chronic inflammation with insulin
resistance, waist hip ratio (WHR) serum testosterone, and serum glutamate pyruvate
transaminase (SGPT) were examined.
Results: In group A, the hsCRP, TNFα, and PMP were significantly elevated
compared to group B. However, IL-6 level was similar between the groups. In group
A, PMP showed a significant positive correlation with waist-hip ratio and serum
testosterone. IL-6 showed a significant positive correlation with insulin sensitivity and
significant negative correlation with insulin resistance and serum glutamate pyruvate
transaminase.
Conclusion: PCOS is associated with chronic inflammation and PMP correlates
positively with central adiposity and biochemical hyperandrogenism in women with
PCOS.
Key words: Polycystic ovary syndrome, Inflammation, C-reactive protein, Interleukin-6,
Tumor necrosis factor, Microparticles.
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1. Introduction
Polycystic ovary syndrome (PCOS) is the most
common endocrinopathy in women of reproductive
age (1). Women with PCOS are often insulin
resistant leading to impaired glucose tolerance
(IGT), metabolic syndrome, and dyslipidemia
which markedly increases the risk of developing
diabetes and cardiovascular disease (CVD) (2-
5). Present body of epidemiological evidence,
though inconclusive, suggests increased CVD-
related mortality and morbidity in PCOS which
is largely mediated through raised total and
abdominal adiposity, with a possible interaction
with PCOS-related hyperandrogenism (6). In
several studies using markers like highly sensitive
C-reactive protein (hsCRP), interleukin-6 (IL-6)
and tumour necrosis factor alpha (TNFα), a link
has been shown between chronic inflammation
and development of cardiovascular disease and
diabetes (7-9). Platelet microparticle (PMP) is a
novel marker which has been shown to have a
role in chronic inflammation, vascular dysfunction,
and CVD (10). Several studies have evidenced
the presence of chronic inflammation in PCOS
but there are also contradicting studies (11-16).
Nevertheless, it still remains unclear whether the
primary factor affecting inflammation is insulin
resistance, central adiposity, or androgen excess,
although most of the evidence points to the first
two factors (16, 17). Moreover, there are several
studies on PCOS in Caucasians, but there is a
scarcity of published data regarding inflammation
in PCOS among Indian women with PCOS (18).
Globally, there is meagre published data regarding
PMP in PCOS (19, 20) but none from Asia in this
regard.
Therefore, this study was designed with the
primary objective of examining the existence of
chronic inflammation in PCOS using PMP, hsCRP,
TNFα, and Il-6 by comparing them with healthy
control. The secondary objective of this study
was to evaluate the correlation of inflammatory
markers with obesity, insulin resistance, and
testosterone in women with PCOS. This will help
determine the presence and etiology of the risk
for CVD and diabetes in Indian women with PCOS
and identify targets for therapy and treatment
monitoring.
2. Materials and Methods
2.1. Participants
For the purpose of this case-control study,
30 women with PCOS (Group A) were selected
from those attending the Endocrinology OPD
of Institute of Postgraduate Medical Education
& Research and Seth Sukhlal Karnani Memorial
Hospital; Hospital and 30 controls (Group B) were
selected from the hospital staff between January
2012 to December 2012. The inclusion criteria
were: (i) women with PCOS diagnosed through
the ESHRE/ASRM criteria, aged 15-40 yr after the
exclusion of related disorders (serum prolactin,
thyroid-stimulating hormone were done in all cases
and 17 hydroxyprogesterone when indicated); (ii)
Controls had regular menstrual periods with no
clinical or biochemical hyperandrogenism. The
exclusion criteria were: (i) Regular or recent
medication intake; (ii) CVD or diabetes; and (iii)
Recent surgery or trauma, infections, chronic
systemic illness, addiction.
2.2. Study design
Anthropometry was done to determine the
patients’ the women body mass index (BMI) and
waist-hip ratio (WHR). Blood was drawn within 10
days of the onset of menses in oligomenorrheic
PCOS women and controls and randomly in
amenorrhoeic PCOS women after overnight
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fast to determine the fasting plasma glucose,
fasting serum insulin, serum testosterone,
PMP, hsCRP, IL-6, TNFα, and serum glutamate
pyruvate transaminase (SGPT). Homeostatic
model assessment of insulin resistance (HOMA-
IR) was determined with the equation fasting
glucose (mg/dl) × fasting insulin (μU/mL)/405 and
quantitative insulin sensitivity check index (QUICKI)
was calculated using the equation 1/[log (I (0)) +
log (G (0))] {where fasting insulin is (I (0)) and
glucose is (G (0))} with a calculator available at
https://sasl.unibas.ch/11calculators-QUICKI.
2.3. Measurement of PMPs
Platelets were obtained from venous blood,
centrifuged at 350 g for 15 min with a buffer
containing 145 mM NaCl, 2.7 mM KCl, 10 mM
HEPES, 0.1% BSA, pH 6.5 (buffer A), followed
by resuspension in the same buffer with pH 7.4
(buffer B). Platelet concentration was adjusted by
buffer B to 2.0-3.0 X 105/μl in order to prepare
PMPs. Platelets activation was done by calcium
ionophore A23187 (10 μM) for 15 min at 37°C
(14) and then centrifuged at 350 g for 15 min to
allow sedimentation. Supernatant collection was
done and centrifuged additionally at 16,000 g
for 30 min. Washing of sedimented microparticles
were performed once followed by resuspension
in buffer B. Aliquots of 5 μl of each suspension
were added to 40 μl of the same buffer containing
additional CaCl2 (2.5 mM). Moreover, 5 μl anti-
CD41-PerCP and anti-CD62P-PEwere added to this
mixture followed by incubation for 20 min at room
temperature in the dark. Sample dilution with 300
μl of the same buffer was used to stop the reactions
and ere immediately analyzed by flow cytometry.
Acquisition was gated to include only the particles
distinctly positive for anti-CD41-PerCP in order to
differentiate platelets and PMPs from background
light scatter.
2.4. Measurement of other
inflammatory markers
hsCRP present in the sample was measured
by typical two-step sandwich enzyme-linked
immunosorbent assay (ELISA) using the kit of
Immuno Biological Laboratories (catalog no.
IB59126, Minneapolis, USA), while IL6 and TNFα
were measured by sandwich ELISA using the kit
of Peprotech (catalog no. 900-K16, Rockhill, USA)
according to the manufacturer’s instructions.
2.5. Ethical considerations
Appropriate permission from the Institutional
Ethics Committee of IPGME & R and SSKM
Hospitals, Kolkata was obtained before beginning
the study (code: IEC 1099A). This study was non-
interventional and informed consent was obtained
from all cases and controls before inclusion.
2.6. Statistical analysis
PMP, hsCRP, IL-6, and TNFα were compared
between the study and control groups using
unpaired t test with correction for BMI and
WHR using multivariate analysis of covariance
for confounding variables. The relationship of
inflammatory markers with anthropometric and
biochemical parameters were determined by
bivariate correlation and Pearson’s correlation
coefficient was estimated. Data were analyzed
using the SPSS Statistics for Windows, version 16.0
(SPSS Inc., Chicago, Ill., USA). A p-value of < 0.05
was considered as statistically significant.
3. Results
Table I shows the age and anthropometric
indices of the study population. The age of Group
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B was significantly greater than the cases, while
both BMI and WHR were significantly greater
in the group A and therefore the multivariate
analysis of covariance was performed to correct
these confounders. PMP, hsCRP, and TNFα were
significantly greater in the cases compared to
controls while there was no difference in the IL-6
between the groups (Table II). In group A, bivariate
correlation was done to determine the Pearson’s
correlation coefficient (r) between inflammatory
markers and biochemical and anthropometric
parameters (Table III). A significant positive
correlation was seen between the PMPs, WHR
and serum testosterone. IL-6 showed a significant
positive correlation with QUICKI and significant
negative correlation with SGPT and HOMA-IR.
There was no significant correlation of PMPs
with BMI, SGPT, HOMA-IR, or QUICKI. Also, no
significant correlation was observed between IL-6
and BMI, WHR, or serum testosterone. hsCRP and
TNFα did not have significant correlation with any
of the anthropometric or biochemical parameters.
Table I. Age and anthropometric indices of study population
Parameter Group A (n = 30) Group B (n = 30) P-value
Age (yr) 22.20 ± 8.32 27.60 ± 4.51 0.003
BMI (kg/m2) 27.48 ± 4.41 24.18 ± 2.08 0.001
WHR 0.87 ± 0.06 0.82 ± 0.04 ≤ 0.001
BMI: Bodymass index, WHR:Waist–hip ratio, Student’s t test was used to compare the age and anthropometric indices between
groups A and B
Table II. Inflammatory markers in the study population
Parameter Group A (n = 30) Group B (n = 30) P-value
PMP/μL 204.4 ± 86.27 115.5 ± 37.24 0.000
hsCRP (mg/L) 0.54 ± 0.32 0.31 ± 0.23 0.012
IL-6 (pg/ml) 7.15 ± 4.09 7.7 1± 2.92 0.117
TNF𝛼 (pg/ml) 21.56 ± 11.15 16.73 ± 6.50 ≤ 0.001
PMP: Platelet microparticle, hsCRP: Highly sensitive C-reactive protein, IL-6: Interleukin 6, TNFα: Tumor necrosis factor alpha
Multivariate analysis of covariance was used to correct the varying baseline parameters (age, BMI, WHR) to avoid confounding
and thereafter compare inflammatory markers between groups A and B
Table III. Correlation between inflammatory markers and biochemical and anthropometric parameters in group A
Parameter PMP hsCRP IL-6 TNF𝛼
r –0.041 –0.100 0.309 –0.143BMI
p 0.830 0.599 0.097 0.451
r 0.402 –0.244 –0.224 –0.152WHR
p 0.027 0.194 0.235 0.426
r –0.136 –0.229 –0.617 –0.168SGPT
P 0.474 0.223 0.000 0.375
r 0.249 –0.214 –0.432 0.115HOMA-IR
p 0.185 0.257 0.017 0.547
r –0.119 –0.039 0.615 0.174QUICKI
p 0.531 0.836 0.000 0.359
r 0.660 –0.286 –0.080 0.199TES
p 0.000 0.125 0.673 0.293
BMI: Body mass index, WHR: Waist–hip ratio, SGPT: Serum glutamate pyruvate transaminase, HOMA-IR: Homeostatic model
assessment of insulin resistance, QUICKI: Quantitative insulin sensitivity check index, TES: Serum testosterone, PMP: Platelet
microparticle, hsCRP: Highly sensitive C-reactive protein, IL-6: Interleukin 6, TNFα: Tumor necrosis factor alpha, Bivariate
correlation was done to determine Pearson’s correlation coefficient (r) between obesity parameters, insulin resistance markers,
and serum testosterone with markers of chronic inflammation in group A
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4. Discussion
In the present study, we evaluated 30 women
with PCOS and 30 controls. The cases were
included based on the Rotterdam criteria, while
the controls were women with regular menses
and no clinical or biochemical evidence of
hyperandrogenism. PMP, hsCRP, and TNFα were
significantly higher in the cases compared to the
controls, while there was no significant difference
in the IL-6 levels between the two groups. These
findings corroborated with those of several other
studies in published literature.
Similar to our study which showed elevated PMP
in women with PCOS compared to controls, two
separate studies conducted in Greece showed that
PMP were elevated compared to the BMI and WHR
ratio-matched controls in both lean and obese
women with PCOS (19, 20).
Kelly et al first demonstrated increased CRP
levels in PCOS compared to controls in 2001 and
several subsequent studies have shown similar
findings (12). In a Korean study, it was showed that
in lean women with PCOS, the hs-CRP level was
higher in the impaired glucose regulation group
than in the normal glucose tolerance group (21).
Another study showed increased CRP levels in
women with PCOS compared to controls (22). In a
study from India, hsCRP was elevated in women
with both newly diagnosed and on-treatment
women with PCOS compared to healthy volunteers
(23). Circulating CRP was shown to be 96% higher
in women with PCOS compared to controls in a
meta-analysis of 31 articles. This finding held good
even after excluding 5 studies with mismatched
body mass and/or obesity frequency between
women with PCOS and controls (11). However,
in another Indian study, the hsCRP level was
not significantly higher in women with PCOS
compared to controls (18). Overall, as has been
discussed, the majority of studies in published
literature refer to increased levels of hsCRP
in PCOS which was what was found in our
study.
Serum TNFαwas found to be significantly higher
in women with PCOS compared to controls in
two separate studies from India and Turkey (13,
22). In an American study, TNF-α was significantly
increased in obese adolescent girls with PCOS
(BMI ≥ 27 kg/m2) when compared with BMI
and age-matched controls (24). These findings
are in agreement with our study which similarly
showed an increase in TNFα in women with PCOS.
However, a meta-analysis of nine studies showed
no statistically significant difference in TNF-α levels
between PCOS and controls (25).
A meta-analysis of 10 studies revealed no
statistically significant difference in IL-6 between
PCOS and controls (25). These findings are similar
to our study where no significant difference was
noted in the IL-6 level between PCOS women
and controls. However, there are published studies
with dissimilar findings. In an Indian study, women
with both newly diagnosed and on-treatment PCOS
exhibited higher plasma concentrations of IL-6 than
healthy volunteers (23). In an Italian study, IL-6 was
found to be significantly increased in all insulin-
resistant PCOS, independent of BMI, but there was
no increase in serum TNFα levels (26). Likewise,
a study from Taiwan showed significantly elevated
levels of IL-6 in PCOS women compared to controls
(27).
In our study, there was a significant positive
correlation between PMPs and WHR and serum
testosterone. In a study in lean women with PCOS,
elevated plasma PMPs in PCOS women correlated
with serum testosterone levels suggesting that
hyperandrogenemia is primarily responsible for
the elevated plasma PMPs in women with PCOS.
However, it did not correlate with adiposity or
impaired glucose metabolism in this study (19).
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In another study in obese women with PCOS,
plasma PMPs did not correlate with the markers
of insulin resistance and serum testosterone.
However, they were higher in the group with more
insulin resistance, higher serum testosterone, and
an increased number of follicles suggesting an
association with androgens and insulin resistance
(20).
In our study, neither hsCRP nor TNFα had
any significant correlation with any of the
anthropometric or biochemical parameters
measured. This finding was similar to a study
which reported no correlation between TNFα and
BMI in adolescent girls with PCOS (24). In another
study from Brazil, hsCRP was higher in obese
women with PCOS compared to lean women with
PCOS but TNFα was similar between the two
groups (16). However, a study from Turkey showed
the presence of significant correlation of both CRP
and TNFα with free androgen index (22).
In our study, IL-6 showed a significant positive
correlation with QUICKI and a significant negative
correlation with SGPT and HOMA-IR. An animal
study comparing IL-6−/− mice with littermate
control mice demonstrated that mice in the
absence of IL-6 develop glucose intolerance and
insulin resistance. Also, IL-6−/− mice showed
signs of hepatic inflammation (28). The role of IL-
6 in T2DM development is still an unanswered
question. Although studies point to the role
of IL-6 in impairment of insulin signaling in
adipocytes in vitro, a similar finding has not
been demonstrated in vivo. Skeletal muscle insulin
resistance has been shown to be unrelated to
long term IL-6 stimulation and further studies
are necessary in this area (29). In our study,
IL-6 did not have a significant correlation with
obesity parameters but in another study, IL-6
was significantly greater in obese women with
PCOS compared to lean women with PCOS
(16).
The discrepancies noted between our study and
certain studies in published literature could be due
to differences in inclusion criteria, ethnicity, and
sample size, and this controversy may be resolved
in the future with studies including a larger number
of women with PCOS.
5. Conclusion
We conclude that PCOS is associated with
chronic inflammation and that PMPs correlate
positively with central adiposity and biochemical
hyperandrogenism in womenwith PCOS. Targeting
central adiposity and hyperandrogenism with our
present therapeutic armamentarium could be a
possible avenue for reducing cardiovascular risk
in women with PCOS with prospective randomized
controlled trials necessary to provide the accurate
answer in the future. Also, PMPs could serve as
a novel futuristic therapeutic target to minimize
inflammation and CVD in women with PCOS.
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